The IMID Forum

Prof Iain McInnes discusses papers on filgotinib and the involvement of pain in RA.

Keep-up to date with the latest in arthritis and cytokine signalling with Prof Iain McInnes. Everything discussed is available in a more detailed slide format in the publications section at cytokinesignalling.com.

Founder and President of the Association of Women in Rheumatology. In this podcast Dr Grace C Wright discusses her careeer and the future of AWIR.

Perspectives in Inflammation is a series of in-depth interviews revealing what attracted world-leading experts to the field of inflammation, their current research interests, and views on the latest developments in inflammation.

Professor György Nagy from the Semmelweis University, Hungry.

Join Prof Peter Nash as he interviews notable figures in rheumatology. In this edition Professor György Nagy discusses his latest paper on EULAR definition of difficult-to-treat RA

Professor Philip Mease from the University of Washington School of Medicine.

Join Prof Peter Nash as he interviews notable figures in rheumatology. In this edition Professor Philip Mease discusses his latest paper on Upadacitinib for Psoriatic Arthritis refractory to biologics.

Prof Iain McInnes discusses JAK inhibitors and TNFi in RA treatment.

Keep-up to date with the latest in arthritis and cytokine signalling with Prof Iain McInnes. Everything discussed is available in a more detailed slide format in the publications section at cytokinesignalling.com.

In this podcast the Past President of ACR, Professor Michael Weinblatt discusses his involvement in the development of methotrexate and the expansion of his unit at the Brigham, alongside Professor Paul Emery. Perspectives in Inflammation is a series of in-depth interviews revealing what attracted world leading experts to the field of inflammation, their current research interests, and views on the latest developments in inflammation.

Prof Josef Smolen from Medical University of Vienna. Join Prof Peter Nash as he interviews notable figures in rheumatology. In this edition Prof Josef Smolen discusses efficacy of baricitinib in patients with RA

Dr Andreas Kerschbaumer from Vienna University. Join Prof Peter Nash as he interviews notable figures in rheumatology. In this edition Dr Andreas Kerschbaumer discusses his systematic review paper on “Points to Consider for the Treatment of Immune Mediated Inflammatory Diseases with Janus Kinase Inhibitors

Professor Roy Fleischmann, from the University of Texas Southwestern Medical Centre in Dallas, discusses data from the SELECT-COMPARE trial, where patients with RA were switched between upadacitinib and adalimumab in cases of insufficient response.

Prof Kevin Winthrop from OHSU. Join Prof Peter Nash as he interviews notable figures in rheumatology. In this edition Prof Kevin Winthrop discusses aged based incidence of infections with tofacitinib